Abstract：
OBJECTIVE: To determine the therapeutic indications for systemic medical treatment in the management of salivary gland carcinoma (excluding adenoid cystic carcinoma) according to the clinical situation.
METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: Salivary gland carcinoma is rare and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, initial management can be based on a phase of monitoring for indolent disease. Some histological subtypes (salivary duct carcinoma and adenocarcinoma) are more aggressive and require systemic treatment from the outset. To guide systemic treatment, it is recommended to perform immunohistochemistry and molecular biology analyses (overexpression of HER2 and androgen receptors, NTRK fusion, next-generation sequencing).
CONCLUSIONS: Salivary gland carcinoma is a rare tumor for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.
METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: Salivary gland carcinoma is rare and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, initial management can be based on a phase of monitoring for indolent disease. Some histological subtypes (salivary duct carcinoma and adenocarcinoma) are more aggressive and require systemic treatment from the outset. To guide systemic treatment, it is recommended to perform immunohistochemistry and molecular biology analyses (overexpression of HER2 and androgen receptors, NTRK fusion, next-generation sequencing).
CONCLUSIONS: Salivary gland carcinoma is a rare tumor for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.
摘要：
目的：根据临床情况确定涎腺癌（不包括腺样囊性癌）的全身药物治疗的适应证。
方法：法国罕见头颈部肿瘤网络（REFCOR）成立了一个指导小组，该小组对Medline上发表的文献进行了叙述性综述，并提出了建议。然后由评级小组评估对建议的遵守程度，根据正式共识方法。
结果：涎腺腺癌是罕见的，目前没有足够的证据表明化疗在局部阶段。在转移阶段，初始管理可以基于对惰性疾病的监测阶段。一些组织学亚型（涎管癌和腺癌）更具侵袭性，从一开始就需要全身治疗。指导全身治疗，建议进行免疫组织化学和分子生物学分析（HER2和雄激素受体的过表达，NTRK聚变,下一代测序)。
结论：涎腺癌是一种罕见的肿瘤，目前尚无有效的药物治疗方法。因此，建议将患者纳入临床试验。
方法：法国罕见头颈部肿瘤网络（REFCOR）成立了一个指导小组，该小组对Medline上发表的文献进行了叙述性综述，并提出了建议。然后由评级小组评估对建议的遵守程度，根据正式共识方法。
结果：涎腺腺癌是罕见的，目前没有足够的证据表明化疗在局部阶段。在转移阶段，初始管理可以基于对惰性疾病的监测阶段。一些组织学亚型（涎管癌和腺癌）更具侵袭性，从一开始就需要全身治疗。指导全身治疗，建议进行免疫组织化学和分子生物学分析（HER2和雄激素受体的过表达，NTRK聚变,下一代测序)。
结论：涎腺癌是一种罕见的肿瘤，目前尚无有效的药物治疗方法。因此，建议将患者纳入临床试验。
